Drug Trial News

RSS

Magnetism does not cause paranormal experiences

Previous research has shown that paranormal experiences can be achieved via electromagnetic stimulation of the temple lobe. Now scientists from Uppsala and Lund universities in Sweden are calling into question how the experiments were set up and therefore questioning the results.

7 Dec 2004

Thalidomide shows promise in fighting myeloma

Thalidomide, a drug often used to treat symptoms of leprosy and in testing to fight HIV, is now demonstrating activity in fighting a common cancer that occurs in bone marrow, myeloma.

6 Dec 2004

Study on methylisothiazolinone in shampoo lacks a credible scientific basis

Consumers can rest assured that their cosmetic products, including shampoos, are safe. The abstract on Methylisothiazolinone (MI), presented at the Cell Biology 2004 meeting of the American Society for Cell Biology, lacks a credible scientific basis in suggesting that MI could be a safety issue for consumers using personal care products.

6 Dec 2004

Cognitive behaviour therapy helps adolescents with chronic fatigue syndrome

Psychological support, in the form of cognitive behaviour therapy, is an effective treatment for adolescents with chronic fatigue syndrome, finds a new study published on bmj.com today.

6 Dec 2004

Month of birth linked to risk of multiple sclerosis

In the northern hemisphere, being born in May is linked to an increased risk of developing multiple sclerosis later in life, while being born in November carries the lowest risk, finds a new study published on bmj.com today.

6 Dec 2004

Majority of hospitalizations for asthma may be the result of people not taking their inhaled steroid medications

Inhaled steroids have become the standard in the treatment of persistent asthma. They have been shown to significantly improve asthma symptoms and reduce asthma complications. However, adherence to the prescribed inhaled steroids is poor among adult asthma patients.

6 Dec 2004

Self-confidence workshops improve depressive symptoms

Self-confidence workshops improve depressive symptoms, distress and self-esteem significantly, according to a study published in the December issue of the British Journal of Psychiatry.

6 Dec 2004

Mental disorders and suicide attempts are caused by social factors

Findings from a new study from Australia suggest that mental disorders and suicide attempts are caused by social factors. There is a need for social and economic responses beyond provision of mental health services.

6 Dec 2004

Family history not age greatly affects breast cancer risk

CancerBACUP has published the results of a survey revealing that more over 50s believe that family history - not age - greatly affects breast cancer risk.

6 Dec 2004

Common ingredient in some shampoos (methylisothiazolinone) stunts developing neurons of rats

An antimicrobial agent found in some shampoos and hand creams and widely used in industrial settings inhibits the development of particular neuron structures that are essential for transmitting signals between cells.

6 Dec 2004

Two recent studies are souring milk's image among health authorities

Two recent studies are souring milk's image among health authorities. One, published in the November issue of the American Journal of Clinical Nutrition, shows that women who consume two or more glasses of milk a day have twice the risk of a certain form of ovarian cancer than those who rarely or never consume milk.

6 Dec 2004

Study shows internet use can lead to fitness

People using the Internet as a guide to getting active were just as successful as those using face-to-face briefings.

6 Dec 2004

TV sporting advert breaks expose children to violent and unsafe behavior

Children watching commercials aired during televised sports events may frequently be exposed to violent and unsafe behavior, a study by a Penn State Children's Hospital physician suggests.

6 Dec 2004

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Results from a clinical trial presented at the American Society of Hematology 46th Annual Meeting and Exposition (ASH) demonstrated that Zevalin (ibritumomab tiuxetan), administered as a first-line therapy, induced a 100 percent response rate in a small population of patients with low-grate follicular lymphoma (FL).

6 Dec 2004

Study shows long-term benefits for chronic myeloid leukemia patients receiving therapy with imatinib

CHU in Poitiers, France, yesterday announced results of a study showing that newly diagnosed patients with a certain form of leukemia who are treated early with imatinib are more likely to achieve complete cytogenetic responses (the elimination of leukemic cells, a major goal of therapy) and have improved long-term outcomes.

6 Dec 2004

Hydroxyurea plus aspirin best therapy in patients with essential thrombocythemia who are at high risk for vascular events

A new treatment for an incurable blood disorder proves a worse option for patients' health than an older treatment, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Genetic target found for pediatric leukemia

A molecular target newly discovered by scientists at two prestigious research institutes may pave the way for new treatments that could combat an aggressive form of leukemia, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Bcl-6 oncogene - genetic target for lymphoma treatment

Results from a pre-clinical study show that the gene designated Bcl-6 is an oncogene -- that is, one with the potential to cause a normal cell to become cancerous -- but that certain peptide inhibitors can in effect inactivate it, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

A new treatment for patients with chronic myeloid leukemia

A new treatment for patients with chronic myeloid leukemia (CML) -- a disorder marked by an overproduction of white blood cells -- yields positive results in those who have relapsed on imatinib, the standard treatment for the disease, according to a Phase I study to be presented today at the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Genasense shown to enhance the anti-lymphoma activity of Velcade and Rituxan

Genta Incorporated announced that two new studies have shown that Genasense (oblimersen sodium) Injection, the Company's lead anticancer drug, showed synergistic activity with both bortezomib (Velcade; Millennium Pharmaceuticals, Inc.) and rituximab (Rituxan; Genentech, Idec) in experimental models of B-cell non-Hodgkin's lymphoma (NHL).

5 Dec 2004